<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060255</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000301587</org_study_id>
    <secondary_id>RPCI-DS-9115</secondary_id>
    <nct_id>NCT00060255</nct_id>
  </id_info>
  <brief_title>High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors</brief_title>
  <official_title>Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in&#xD;
      chemotherapy use different ways to stop cancer cells from dividing so they stop growing or&#xD;
      die. Combining chemotherapy with autologous stem cell transplantation or autologous bone&#xD;
      marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and&#xD;
      kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well eight different high-dose chemotherapy&#xD;
      regimens with or without total-body irradiation followed by autologous stem cell&#xD;
      transplantation or autologous bone marrow transplantation works in treating patients with&#xD;
      hematologic malignancies or solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the morbidity, mortality, and overall outcome in patients with hematologic&#xD;
           malignancies, breast cancer, or other chemosensitive solid tumors treated with&#xD;
           disease-specific dose-intensive conditioning regimens and autologous peripheral blood or&#xD;
           bone marrow transplantation.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to risk group (standard vs high). Standard risk&#xD;
      includes acute leukemia in first relapse or second remission; lymphoma in responding first&#xD;
      relapse or second remission; or breast cancer at risk for recurrence. High risk includes all&#xD;
      others. Patients receive specific conditioning regimens according to diagnosis as outlined&#xD;
      below.&#xD;
&#xD;
      Conditioning&#xD;
&#xD;
        -  Regimen A (standard risk non-Hodgkin's lymphoma and under 60 years of age)-Etoposide,&#xD;
           cyclophosphamide, and total body irradiation (TBI) (VCT): Patients receive etoposide IV&#xD;
           continuously over 26 hours beginning on day -5 and cyclophosphamide IV over 2 hours on&#xD;
           day -4. Patients undergo TBI on days -3 to -1.&#xD;
&#xD;
        -  Regimen B (any risk Hodgkin's lymphoma and under 60 years of age)-Cyclophosphamide,&#xD;
           carmustine, and etoposide (CBV): Patients receive etoposide IV continuously over 34&#xD;
           hours beginning on day -8; cyclophosphamide IV over 2 hours on days -7 to -4; and&#xD;
           carmustine IV over 2 hours on day -3.&#xD;
&#xD;
        -  Regimen C (any risk patient with prior exposure to high-dose etoposide and&#xD;
           cyclophosphamide and under 60 years of age)-Melphalan and TBI (MEL/TBI): Patients&#xD;
           receive melphalan IV over 30 minutes on day -4. Patients undergo TBI on days -3 to -1.&#xD;
&#xD;
        -  Regimen D (multiple myeloma or amyloidosis)-Melphalan only (MEL only): Patients receive&#xD;
           melphalan IV over 30 minutes on day -2.&#xD;
&#xD;
        -  Regimen E (any patient unable to receive TBI)-Busulfan and cyclophosphamide: Patients&#xD;
           receive oral busulfan (or busulfan IV over 2 hours) on days -7 to -4 and&#xD;
           cyclophosphamide IV over 2 hours on days -3 and -2.&#xD;
&#xD;
        -  Regimen F (any risk breast cancer)-Cyclophosphamide, carboplatin, and thiotepa (STAMP&#xD;
           V): Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours,&#xD;
           and thiotepa IV over 24 hours on days -7 to -4.&#xD;
&#xD;
        -  Regimen G (solid tumors other than breast or testicular cancer)-Thiotepa and carboplatin&#xD;
           (TT/CARBO): Patients receive thiotepa IV over 2 hours on days -6 and -5 and carboplatin&#xD;
           IV continuously over 96 hours beginning on day -6.&#xD;
&#xD;
        -  Regimen H (recurrent or primary progressive testicular cancer)-Etoposide and carboplatin&#xD;
           (VP/CARBO): Patients receive etoposide IV over 2 hours and carboplatin IV over 30&#xD;
           minutes on days -6 to -4.&#xD;
&#xD;
      Stem Cell Infusion&#xD;
&#xD;
        -  In all regimens, patients undergo autologous stem cell infusion on day 0. Treatment&#xD;
           continues in the absence of unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 450 patients (50 patients [25 per stratum] per regimen) will&#xD;
      be accrued for this study within 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1991</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>+day 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>+day 100, +day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall outcome</measure>
    <time_frame>every 6 months until death</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>+day 100, +day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>+day100, +day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>up to 15years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 6 months until death</time_frame>
  </primary_outcome>
  <enrollment type="Actual">451</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>iv</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>iv</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>iv</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>iv</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>iv</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>oral</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <description>iv</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
    <description>iv</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
    <description>iv</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>iv</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>body x-ray</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed hematologic or solid tumor malignancy, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
                    -  First remission and not eligible for allogeneic transplantation; recurrent&#xD;
                       disease after combination chemotherapy with at least 1 standard regimen; or&#xD;
                       second remission&#xD;
&#xD;
                    -  Not eligible for protocol CLB-9620 or CLB-9621&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
                    -  First complete remission without appropriate allogeneic donor&#xD;
&#xD;
               -  Chronic myelogenous leukemia&#xD;
&#xD;
                    -  Chronic, accelerated, or blast phase&#xD;
&#xD;
               -  Lymphoproliferative diseases*&#xD;
&#xD;
                    -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Multiple myeloma&#xD;
&#xD;
                    -  Waldenstrom's macroglobulinemia&#xD;
&#xD;
                    -  Low-grade non-Hodgkin's lymphoma (NHL) NOTE: *Recurrent or persistent,&#xD;
                       symptomatic disease after first-line chemotherapy, or subsequently&#xD;
&#xD;
               -  Amyloidosis&#xD;
&#xD;
                    -  Primary or previously treated disease&#xD;
&#xD;
               -  NHL (intermediate- and high-grade)&#xD;
&#xD;
                    -  Resistant or recurrent disease after combination chemotherapy with at least&#xD;
                       1 standard regimen&#xD;
&#xD;
                    -  First remission lymphoblastic or small, non-cleaved cell lymphoma at high&#xD;
                       risk of relapse&#xD;
&#xD;
                         -  CNS disease OR bone marrow disease and lactic dehydrogenase greater&#xD;
                            than 300 IU/L&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
                    -  Resistant or recurrent disease after combination chemotherapy with at least&#xD;
                       1 standard regimen&#xD;
&#xD;
               -  Solid tumors&#xD;
&#xD;
                    -  High-risk and metastatic breast cancer&#xD;
&#xD;
                    -  Testicular cancer that has relapsed OR primary progressive disease that is&#xD;
                       responding to salvage therapy&#xD;
&#xD;
                    -  Other solid tumors that have recurred after conventional therapy OR are at&#xD;
                       high risk for relapse, and demonstrate chemosensitivity&#xD;
&#xD;
          -  Less than 10% marrow tumor present histologically (maximum of 15% involvement allowed&#xD;
             if purged)&#xD;
&#xD;
          -  Allogeneic marrow transplantation not possible or not desirable for any of the&#xD;
             following reasons:&#xD;
&#xD;
               -  Over 60 years of age&#xD;
&#xD;
               -  No compatible donor identified&#xD;
&#xD;
               -  Estimated risk of graft-versus-host disease complications greater than risk of&#xD;
                  recurrence after autologous bone marrow transplantation&#xD;
&#xD;
          -  Patients with disease progression in a site of prior radiotherapy (4,000 cGy or more)&#xD;
             are not eligible for total body irradiation (TBI) regimens&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified NOTE: A new classification scheme for adult non-Hodgkin's lymphoma&#xD;
                  has been adopted by PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma&#xD;
                  will replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade&#xD;
                  lymphoma. However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  4 and over (patients 60 years of age and over are not eligible for TBI)&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3*&#xD;
&#xD;
          -  Polymorphonuclear leukocyte count greater than 1,500/mm^3*&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3*&#xD;
&#xD;
          -  Marrow cellularity greater than 20%*&#xD;
&#xD;
          -  No marrow fibrosis* NOTE: *Before marrow storage&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 3 times normal&#xD;
&#xD;
          -  Alkaline phosphatase less than 3 times normal&#xD;
&#xD;
          -  AST less than 3 times normal&#xD;
&#xD;
          -  Hepatitis status known&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min (not required for patients with amyloidosis or&#xD;
             multiple myeloma)&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ventricular ejection fraction at least 50% by radionuclide ventriculogram or&#xD;
             echocardiogram&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No symptomatic angina&#xD;
&#xD;
          -  No life-threatening arrhythmia or hypertension&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO or DLVA at least 50% of predicted (DLCO must be corrected for hemoglobin and/or&#xD;
             alveolar ventilation)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Cytomegalovirus status known&#xD;
&#xD;
          -  No active bacterial, viral, or fungal infection&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No serious organ dysfunction unless it is caused by the underlying disease&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude giving informed&#xD;
             consent or complying with study requirements&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior cumulative nitrosourea dose greater than 600 mg/m^2&#xD;
&#xD;
          -  No prior cumulative bleomycin dose greater than 150 units/m^2&#xD;
&#xD;
          -  No prior cumulative doxorubicin dose greater than 450 mg/m^2&#xD;
&#xD;
          -  No prior cumulative daunorubicin dose greater than 600 mg/m^2&#xD;
&#xD;
          -  Patients with prior high-dose cyclophosphamide (greater than 150 mg/kg per cycle) and&#xD;
             high-dose etoposide (greater than 2,400 mg/m^2 per cycle) are not eligible for the&#xD;
             etoposide/cyclophosphamide/TBI conditioning regimen&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy (before blood stem cell harvest)&#xD;
&#xD;
          -  Prior cumulative doses of radiotherapy must not exceed the following:&#xD;
&#xD;
               -  Spine/spinal cord: 4,000 cGy&#xD;
&#xD;
               -  Mediastinum: 4,000 cGy&#xD;
&#xD;
               -  Heart: 4,000 cGy&#xD;
&#xD;
               -  Kidney (whole): 1,500 cGy&#xD;
&#xD;
               -  Small bowel: 4,000 cGy&#xD;
&#xD;
               -  Brain: 4,000 cGy&#xD;
&#xD;
               -  Liver (whole): 2,000 cGy&#xD;
&#xD;
               -  Lungs (whole): 1,500 cGy&#xD;
&#xD;
               -  Bone: 5,000 cGy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip L. McCarthy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>May 7, 2013</last_update_submitted>
  <last_update_submitted_qc>May 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

